Targeting Immunometabolism in Autoimmune Diseases and Inflammation conference

Published on 25/09/2019

22 October, 2019
New-York, USA

ENYO Pharma will participate to the “Targeting Immunometabolism in Autoimmune diseases and Inflamamtion conference” in New York and will present a poste entitled “A novel small molecule modulating mitochondrial activity improves inflammation in a diet-induced NASH model”

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US